In the last trading session, 10.02 million shares of the Capricor Therapeutics Inc (NASDAQ:CAPR) were traded, and its beta was 4.04. Most recently the company’s share price was $21.65, and it changed around $4.58 or 26.83% from the last close, which brings the market valuation of the company to $704.49M. CAPR currently trades at a discount to its 52-week high of $18.14, offering almost 16.21% off that amount. The share price’s 52-week low was $2.68, which indicates that the current value has risen by an impressive 87.62% since then. We note from Capricor Therapeutics Inc’s average daily trading volume that its 10-day average is 12.91 million shares, with the 3-month average coming to 2.16 million.
Capricor Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended CAPR as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Capricor Therapeutics Inc is expected to report earnings per share of -0.36 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Capricor Therapeutics Inc (NASDAQ:CAPR) trade information
Instantly CAPR has showed a green trend with a performance of 26.83% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 21.98 on recent trading dayincreased the stock’s daily price by 1.5%. The company’s shares are currently up 342.74% year-to-date, but still up 117.59% over the last five days. On the other hand, Capricor Therapeutics Inc (NASDAQ:CAPR) is 410.61% up in the 30-day period. We can see from the shorts that 7.53 million shares have been sold at a short interest cover period of 33.86 day(s).
The consensus price target as assigned by Wall Street analysts is $25, which translates to bulls needing to increase their stock price by 13.4% from its current value. Analyst projections state that CAPR is forecast to be at a low of $15 and a high of $40.
Capricor Therapeutics Inc (CAPR) estimates and forecasts
Capricor Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 222.17 percent over the past six months and at a -36.14% annual growth rate that is well below the industry average of 12.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -44.00% in revenue this quarter, and will report a decrease of -1,650.00% in the next quarter. The year-over-year growth rate is expected to be -35.60%, down from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 3.58M in revenue for the current quarter. 4 analysts expect Capricor Therapeutics Inc to make 4.1M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 6.19M and 12.09M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -42.10%. Forecasts for the next quarter put sales growth at -66.10%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 30.59%.
CAPR Dividends
Capricor Therapeutics Inc’s next quarterly earnings report is expected to be released in November.
Capricor Therapeutics Inc (NASDAQ:CAPR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 23.38% of Capricor Therapeutics Inc shares, and 28.51% of them are in the hands of institutional investors. The stock currently has a share float of 37.20%. Capricor Therapeutics Inc stock is held by 87.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 5.194% of the shares, which is about 1.63 million shares worth $7.77 million.
VANGUARD GROUP INC, with 4.9401% or 1.55 million shares worth $7.39 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
